Company History

Management Team

Press Releases

Contact Us


Laser Spine Therapy
Provider List





949.951.3800 EXT. 288


       August 22, 2005 – Irvine, CA: TRIMEDYNE, INC. (OTCBB “TMED”) today reported financial results for the quarter and nine months ended June 30, 2005.  Revenues in the quarter declined 8% to $1,552,000 from $1,696,000 for the prior year quarter, and the Company had a loss in the current quarter of $153,000 or $0.01 per share, versus a net profit of $158,000 or $0.01 per share in the prior year’s quarter.  R & D expenses rose as a result of readying the Company’s new VaporMAX™ Side Firing Fiber for release to the market, and higher sales management costs. 

       For the nine months ended June 30, 2005, revenues increased 10% to $4,783,000 from $4,350,000 for the prior year’s period, but the Company suffered a loss of $4,000 or $0.00 per share, versus a net profit in the nine-month period of the prior year of $472,000 or $0.03 per share.  Other income in the year ago period was $188,000 higher than in the current nine-month period.

       Glenn D. Yeik, President of Trimedyne, said, “We will soon introduce our new VaporMAX™ Side Firing Laser Fiber, which vaporizes tissue faster and is more durable than other laser fibers currently marketed for the treatment of enlarged prostates, based on animal tissue bench testing and published data.  Used with our Holmium Laser for the treatment of benign prostatic hyperplasia (BPH or enlarged prostate), the procedure time is shorter, reducing operating room costs, and one device is sufficient to treat large prostates.  Comparable laser fibers are generally limited to treating medium sized prostates.  Our VaporMAX™ Fiber qualifies for the new, higher APC Medicare reimbursement rate.  While its development cost was significant, we have a backlog of orders for our new VaporMAX™ Fiber and believe it will increase our revenues in the future.”

       Trimedyne manufactures lasers and proprietary fiber optic devices for a variety of minimally invasive surgical procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery.  For product, financial and other information, visit Trimedyne's website,

 "Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

       Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934.  Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent report on Form 10-KSB and subsequently filed SEC reports.  There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.



Home | About Us | Products | Education & Training | Investor Relations | Events
  What's New | Careers | DoublePulse | Site Map | Contact Us

© Copyright 2005 Trimedyne, Inc.  All rights reserved.